Workshop report on some new ideas about the treatment of systemic lupus erythematosus

Lupus

Volumn 11, Issue 12, 2002, Pages 793-796

  Linnik, M ^a   Staines, N A ^b   Berden, J ^c   Isenberg, D A ^d,e  

^a La Jolla Pharmaceutical Company   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e Centre for Rheumatology   (United Kingdom)

Author keywords

Anti DNA antibody; Histone peptide; SLE

Indexed keywords

ABETIMUS; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DNA ANTIBODY; HISTONE; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; MYCOPHENOLIC ACID; PEPTIDE; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG EFFICACY; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; WORKSHOP;

EID: 0036949954     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203302lu320oa     Document Type: Conference Paper

References (14)

1. Sorbera LA, Castaner RM, Revel L. Abetimus sodium. Drugs Future 2001; 26(7): 633-638.
2. Jones DS, Hachmann JP, Osgood SA, Hayag MS, Barstad PA, Iverson GM, Coutts SM. Related articles conjugates of double-stranded oligonucleotides with poly(ethylene glycol) and keyhole limpet hemocyanin: a model for treating systemic lupus erythematosus. Bioconjug Chem 1994; 5(5): 390-399.
3. Jones DS, Barstad PA, Feild MJ, Hachmann JP, Hayag MS, Hill KW, Iverson GM, Livingston DA, Palanki MS, Tibbetts AR et al. Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis. J Med Chem 1995; 38(12): 2138-2144.
4. Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, Liebling MR, Hudson NP, Bemer CM, Coutts S, de Haan HA. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 2001; 28(2): 257-265.
5. Sem DS, McNeeley PA, Linnik MD. Antibody affinities and relative titers in polyclonal populations: surface plasmon resonance analysis of anti-DNA antibodies. Arch Biochem Biophys 1999; 372(1): 62-68.
6. McNeeley PA, Iverson GM, Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, Linnik MD. Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients. Lupus 2001; 10(8): 526-532.
7. Wu HY, Ward FJ, Staines NA. Downregulation ofhumoral and cellular autoimmunity in murine systemic lupus erythematosus via nasal instillation of nucleosome derived peptides. J Immunol (submitted).
8. Derry CJ, Harper N, Davies DH, Murphy JJ, Staines NA. Importance of dose of type II collagen in suppression of collagen-induced arthritis by nasal tolerance. Arthritis Rheum 2001; 44: 1917-1927.
9. Faria AM, Weiner HL. Oral tolerance: mechanisms and therapeutic applications. Adv Immunol 1999; 73: 153-264.
10. Choy EHS, Scott DL, Kingsley GH, Thomas S, Murphy T, Staines NA, Panayi GS. Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum 2001; 44: 1993-1997.
11. Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993; 177: 1367-1381.
12. Kaliyaperumal A, Mohan C, Wu W, Datta SK. Nucleosomal peptide epitopes for nephritis-inducing T helper cells of murine lupus. J Exp Med 1996; 183: 2459-2469.
13. Beech JT, Bainbridge T, Thompson SJ. Incorporation of cells into an ELISA system enhances antigen-driven lymphokine detection. J Immunol Meth 1997; 205: 163-168.
14. Leandro MJ, Edwards JCW, Isenberg DA. An open study for B lymphocyte depletion in systemic lupus erythematosus. Rheumatology 2002; 41: S18.